Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract ...

Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...

Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...

(UroToday.com) The 2026 ASCO annual meeting featured a radioligand innovation in prostate cancer session and a presentation by Dr. Michael Morris discussing CONVERGE-01 Part 3 assessing Ac-225 ...

Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. July 3, 2026 A Quantitative Modification of VI-RADS for Bladder Cancer at ...

(UroToday.com) The 2023 American Urological Association (AUA) annual meeting held in Chicago, IL between April 28 and May 1st, 2023, was host to a plenary session, with Dr. John Wei presenting the ...

First Use of the FloStent™ for Catheter-Dependent Urinary Retention Secondary to BPH: Additional Results from the RAPID I Study - Beyond the Abstract ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured an oral abstract session on urothelial carcinoma, and a presentation by Dr. Daniel Petrylak discussing the ...

ASCO GU 2025 results of a 52-week clinical trial evaluating the safety and tolerability of relugolix in combination with abiraterone or apalutamide, advanced prostate cancer, HERO trial.

AUA 2025 Advanced-2, safety and efficacy of TARA-002 intravesical installations, non-muscle invasive bladder cancer (NMIBC), bladder cancer in the United States.